Alzheimer's Disease

Biotechnology company Cajal Neuroscience announced its launch with $96 million Series A financing with plans to combine human genetics, functional genomics and advanced microscopy to expand drug discovery for neurodegenerative diseases.

Klotho protein levels in cerebrospinal fluid and plasma were associated with clinical stages of Alzheimer’s disease, cognitive decline, and amyloid and tau burden, independent of KL-VS heterozygosity status, according to research.

Researchers at Emory University are developing a visual tool to view how conditions such as Alzheimer's disease and autism spectrum disorder affect the brain in real-time, the university announced in a press release.

A team of researchers at the University of Miami Miller School of Medicine have developed an online platform of metrics designed to assess a patient’s risk for developing Alzheimer’s disease and other neurological issues.

Gantenerumab, a treatment for mild cognitive impairment due to Alzheimer’s disease, did not meet the primary endpoint of slowing cognitive decline in a phase 3 clinical trial, Genentech announced in a released statement.

Cerveau Technologies Inc. has announced a license agreement with Lexeo Therapeutics Inc. that will allow Lexeo to use an investigational imaging agent from Cerveau for the assessment of neurofibrillary tangles in the brain.

CHICAGO — While population and phenotypic diversity are crucial to discovering the root cause of genetic variations that lead to neurodegenerative disease, the answers are not always clear, according to a presenter at ANA 2022.

A team of Penn State University researchers has been awarded a $1.2 million grant from the NIH to develop a machine learning system for the early detection of Alzheimer’s disease.

SAN DIEGO – Athira Pharma’s first intervention trial involving fosgonimeton showed that use of the drug alone showed a “sizable effect” in cognitive improvement at 26 weeks, according to chief medical officer Hans Moebius, MD, PhD.

SAN DIEGO – AmyriAD Therapeutics is focusing on the upregulation of neurotransmission to improve cognition and global function in patients with Alzheimer’s disease, according to CEO Sharon L. Rogers, PhD.